SCHEMBL7148659

SCHEMBL7148659

OCC(Nc1nc(Cl)nc2[nH]cnc12)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 12/20 0.42
AURKA O14965 2/20 0.41
RPS6KB1 P23443 2/20 0.41
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
DYRK3 O43781 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CLK1 P49759 1/20 0.38
CLK3 P49761 1/20 0.38
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
DYRK2 Q92630 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
DYRK4 Q9NR20 1/20 0.38
DYRK1B Q9Y463 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6016639 1.00 EGFR (0.42) EGFRAURKARPS6KB1CCNCCDK8
SCHEMBL5443748 0.83 LMNA (0.35) LMNASMN1; SMN2
SCHEMBL7148662 0.81 XDH (0.50) EGFRLMNASMN1; SMN2
SCHEMBL6016640 0.81 XDH (0.50) EGFRLMNASMN1; SMN2
SCHEMBL7778243 0.81 EGFR (0.56) EGFRAURKARPS6KB1
SCHEMBL14181331 0.81 LMNA (0.50) EGFRLMNAHPGDSMN1; SMN2
SCHEMBL17933851 0.81 LMNA (0.50) EGFRLMNAHPGDSMN1; SMN2
SCHEMBL6016695 0.81 EGFR (0.56) EGFRAURKARPS6KB1
SCHEMBL22524283 0.81 EGFR (0.56) EGFRAURKARPS6KB1
SCHEMBL3445621 0.80 EGFR (0.40) EGFRAURKARPS6KB1CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030187261-A1 Purine derivatives, process for their preparation and use thereof USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2003-10-02 US claimed
US-20030187261-A1 Purine derivatives, process for their preparation and use thereof USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187261-A1 Purine derivatives, process for their preparation and use thereof DCK, DTYMK, CCNK EGFR 3830/4885AURKA 122/4885RPS6KB1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.